Warm congratulations on Ai Xin Zhonghong's successful acquisition of Yunnan Run Cangsheng, NASDAQ to

2022-07-26 12:49

On July 26, 2022, Chengdu Aixin Zhonghong Biotechnology Co., LTD. (hereinafter referred to as Aixin Zhonghong), a subsidiary of Aixin Group, successfully acquired Yunnan Runcang Science and Technology Co., LTD. (hereinafter referred to as Runcang), and the merger agreement has been signed and uploaded to the NASDAQ Securities Regulatory Commission. After the merger, the two companies will become subsidiaries of Aixin Group, and the successful integration into Aixin Group marks a big step on the road of Aixin Group's transition from NASDAQ OTC QX to the main board.



Chengdu Aixin Zhonghong Biotechnology Co., Ltd. was registered in Chengdu Jinniu Industrial and Commercial Bureau on March 4, 2013, with a registered capital of 100 million yuan. The company's business scope includes biotechnology extension services, health consulting, wholesale and retail, pre-packaged food, etc. The company has been adhering to good service as the core, while focusing on the development of the local MARKET, in 2017, Chengdu AIxin Zhonghong Biotechnology Co., Ltd. successfully listed in the United States OTC MARKET (stock code: AIXN), the company's business has been all over the country, the total assets of up to hundreds of millions of yuan, tens of millions of dollars of market value.


Runcangsheng is a deep-processing enterprise of Chinese medicinal materials introduced by Luquan County Party Committee and county government in 2020. It was registered and established in April 2020, and belongs to the science and technology smes in Yunnan Province and the national science and technology smes. The company has more than 20 patents, software Copyrights and more than 30 registered trademarks. It is mainly engaged in the cultivation of Chinese medicinal materials, plateau characteristic agricultural products, processing and sales of food, functional food and health food. The company's products mainly include Chinese herbal decoction pieces, Chinese herbal extracts, powders, tablets, capsules (soft capsules), solid drinks (oral liquid), etc.


The regional advantages and corporate resources of Aixin Zhonghong and Runcangsheng have far-reaching strategic significance for the future development of Aixin Group, which will produce favorable synergies, which will also accelerate the pace of Aixin Group's NASDAQ board transfer, and formally make efforts in 2022 and serve the health industry.


As the leader of China's healthy life management enterprises, Aixin Group has long been committed to elderly health services, escorting the health of the elderly, and creating a "healthy life manager" image. Comprehensively optimize and improve the quality of life of the elderly population, make the elderly seriously "youth", and help them complete their unfinished dreams. By 2022, the company's loyal members have reached 20W people and received numerous praise. It is precisely because of our thoughtful services that we have been able to spread good word of mouth among our consumer groups.


Aixin Group will take this joint opportunity to actively develop the national large health industry service market, and truly realize the "healthy life manager" large health industry service provider. This strategic layout is part of Aixin Group's overall strategy to realize the transition from NASDAQ OTC QX to NASDAQ Main Board. "Be a man with a grateful heart and do business with love", Aixin Group hopes to build such a platform to help more Aixin family realize profits in the company's industry, help more partners achieve their dreams, and finally achieve the great Aixin dream.